# Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

> **NCT01778088** · PHASE2 · WITHDRAWN · sponsor: **Cellectar Biosciences, Inc.**

## Conditions studied

- Glioma

## Interventions

- **DRUG:** I-131-CLR1404 Injection

## Key facts

- **NCT ID:** NCT01778088
- **Lead sponsor:** Cellectar Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-05
- **Primary completion:** 2014-06
- **Final completion:** 2015-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01778088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01778088, "Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01778088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*